Tuesday 20 October 2026
Export INCY’s income statement to Excel — free account
Incyte Corporation
INCY Healthcare Biotechnology
Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
116.27
3.02
+2.67%
Follow INCY
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
14.97 | 222.81 | 24.51 | 51.66 | 17.11 | 0.00 | 41.98 | 122.29 | 0.00 | 182.71 |
Piotroski F-Score |
9 | 5 | 5 | 4 | 4 | 4 | 5 | 7 | 4 | 6 |
P/S ratio |
3.75 | 3.37 | 3.96 | 5.20 | 5.42 | 7.11 | 8.69 | 7.18 | 13.44 | 17.39 |
Altman Z-Score |
8.57 | 5.19 | 6.77 | 8.68 | 9.67 | 12.39 | 14.71 | 11.77 | 17.00 | 9.33 |
P/FCF ratio |
14.50 | 60.83 | 32.60 | 19.80 | 28.46 | 0.00 | 29.67 | 51.40 | 0.00 | 104.20 |
Altman Z″-Score (non-manufacturers) |
7.90 | 3.17 | 7.41 | 6.84 | 6.70 | 3.99 | 6.49 | 4.31 | 2.24 | 0.51 |
Beneish M-Score |
(2.43) | (2.69) | (2.20) | (3.11) | (1.98) | (2.20) | (2.82) | (2.79) | (2.08) | (1.52) |
P/Operating CF |
35.49 | 37.52 | 99.08 | 62.26 | 140.26 | 176.74 | 142.58 | 161.09 | (231.22) | 203.68 |
P/B ratio |
3.73 | 4.15 | 2.82 | 4.04 | 4.29 | 7.26 | 7.22 | 7.01 | 12.66 | 45.83 |
Price to Tangible BV |
3.92 | 4.50 | 2.98 | 4.32 | 4.67 | 8.31 | 8.34 | 8.69 | 16.67 | 3,535.68 |
EV/Sales |
3.06 | 2.87 | 2.98 | 4.26 | 4.65 | 6.45 | 7.74 | 6.43 | 12.69 | 17.24 |
EV/EBITDA |
9.79 | 80.95 | 15.67 | 22.34 | 21.56 | 0.00 | 36.58 | 65.65 | 0.00 | 93.73 |
EV/Operating CF |
11.14 | 36.36 | 22.20 | 14.91 | 18.51 | (138.13) | 23.50 | 35.96 | (209.64) | 62.56 |
EV/FCF |
11.84 | 51.84 | 24.55 | 16.21 | 24.41 | (55.17) | 26.40 | 46.02 | (95.56) | 103.35 |
Quick Ratio |
3.04 | 1.83 | 3.55 | 3.36 | 3.47 | 3.62 | 4.73 | 4.11 | 3.83 | 3.50 |
Current Ratio |
3.32 | 1.97 | 3.75 | 3.54 | 3.65 | 3.74 | 4.83 | 4.31 | 4.01 | 3.64 |
Net Debt/EBITDA |
(2.21) | (14.11) | (5.16) | (4.96) | (3.60) | 8.35 | (4.53) | (7.71) | 5.99 | (0.77) |
Debt/Assets |
0.43% | 0.62% | 0.43% | 0.52% | 0.64% | 0.91% | 1.47% | 0.66% | 1.04% | 39.76% |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 1.55 |
Asset Turnover |
0.83 | 0.69 | 0.59 | 0.63 | 0.70 | 0.76 | 0.71 | 0.76 | 0.78 | 0.84 |
Operating CF/Net income |
1.10 | 10.28 | 0.83 | 2.85 | 0.79 | 0.42 | 1.59 | 3.07 | 0.30 | 2.92 |
Capex/Depreciation |
(0.90) | (1.12) | (0.57) | (1.15) | (3.13) | (3.62) | (1.43) | (1.34) | (2.13) | (2.06) |
Interest Coverage |
623.91 | 26.91 | 243.25 | 217.34 | 307.01 | (121.29) | 216.71 | 83.75 | (35.27) | 3.74 |
| 29.87% | 0.76% | 12.50% | 8.37% | 29.73% | (11.35%) | 19.76% | 6.16% | (30.55%) | 35.29% | |
| 20.75% | 0.53% | 9.47% | 6.32% | 22.33% | (8.46%) | 14.72% | 4.43% | (15.89%) | 7.88% | |
ROIC |
58.55% | 2.90% | 24.81% | 31.19% | 25.19% | (19.56%) | 47.31% | 15.99% | (31.37%) | 34.54% |
Return on Tangible Assets |
30.35% | 1.38% | 14.38% | 9.27% | 31.74% | (12.92%) | 19.05% | 6.34% | (22.54%) | 11.73% |
Average Days of Receivables |
72.73 | 73.42 | 73.44 | 69.34 | 75.33 | 65.97 | 52.21 | 59.66 | 63.27 | 49.11 |
Research and Development Expense of Revenue |
39.88% | 61.46% | 44.04% | 46.72% | 48.83% | 83.10% | 53.46% | 63.66% | 86.32% | 52.62% |
Selling, General and Administrative Expense of Revenue |
26.77% | 29.29% | 31.27% | 29.52% | 24.77% | 19.38% | 21.71% | 23.08% | 23.84% | 27.43% |
Intangible Assets out of Total Assets |
0.04 | 0.05 | 0.04 | 0.05 | 0.06 | 0.09 | 0.10 | 0.14 | 0.17 | 0.25 |
Share Based Compensation of Revenue |
4.85% | 6.27% | 5.84% | 5.55% | 6.13% | 6.67% | 7.72% | 7.87% | 8.66% | 8.70% |
Graham Net Nets |
0.17 | 0.09 | 0.21 | 0.15 | 0.12 | 0.07 | 0.09 | 0.08 | 0.04 | (0.01) |
Graham Number |
62.70 | 10.78 | 37.34 | 26.12 | 40.63 | 0.00 | 23.79 | 10.30 | 0.00 | 5.30 |
Earnings Yield |
6.68% | 0.45% | 4.08% | 1.94% | 5.84% | (1.60%) | 2.38% | 0.82% | (1.55%) | 0.55% |
Free Cash Flow Yield |
6.90% | 1.64% | 3.07% | 5.05% | 3.51% | (1.64%) | 3.37% | 1.95% | (0.99%) | 0.96% |
Revenue per Share |
26.34 | 20.48 | 16.53 | 15.29 | 13.55 | 12.23 | 10.04 | 8.86 | 7.51 | 5.89 |
Operating CF per Share |
7.24 | 1.62 | 2.22 | 4.37 | 3.40 | (0.57) | 3.31 | 1.58 | (0.45) | 1.62 |
Capex per Share |
(0.43) | (0.48) | (0.21) | (0.35) | (0.82) | (0.86) | (0.36) | (0.35) | (0.54) | (0.64) |
Free Cash Flow per Share |
6.81 | 1.14 | 2.01 | 4.02 | 2.58 | (1.43) | 2.94 | 1.24 | (1.00) | 0.98 |
Cash per Share |
18.34 | 10.42 | 16.35 | 14.59 | 10.65 | 8.26 | 9.85 | 6.77 | 5.72 | 4.30 |
Shareholders Equity per Share |
26.47 | 16.65 | 23.21 | 19.68 | 17.10 | 11.97 | 12.09 | 9.07 | 7.97 | 2.23 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
26.47 | 16.65 | 23.21 | 19.68 | 17.10 | 11.97 | 12.09 | 9.07 | 7.97 | 2.23 |
Free Cash Flow |
1,329.63 | 235.17 | 449.00 | 892.11 | 568.48 | (311.98) | 632.59 | 262.74 | (204.01) | 184.48 |
Working Capital |
3,508.73 | 1,597.18 | 3,405.02 | 2,935.77 | 2,264.37 | 1,728.70 | 1,968.15 | 1,406.98 | 1,129.46 | 720.68 |
Capital Expenditures |
(83.87) | (100.16) | (47.49) | (77.83) | (181.01) | (187.38) | (78.06) | (73.48) | (111.02) | (120.28) |
Net Current Asset Value |
3,233.41 | 1,242.34 | 3,053.13 | 2,621.99 | 1,955.33 | 1,410.24 | 1,653.14 | 1,112.46 | 832.90 | (224.95) |
EV/EBIT |
10.39 | 198.68 | 17.76 | 24.96 | 23.69 | 0.00 | 41.54 | 93.58 | 0.00 | 131.49 |
Capex to Sales |
0.02 | 0.02 | 0.01 | 0.02 | 0.06 | 0.07 | 0.04 | 0.04 | 0.07 | 0.11 |
Price to Operating Income |
12.73 | 233.11 | 23.59 | 30.48 | 27.62 | 0.00 | 46.68 | 104.51 | 0.00 | 132.58 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.13 | 0.12 | 0.11 | 0.09 | 0.08 | 0.09 | 0.14 | 0.17 | 0.20 | 0.35 |
Cash ROIC |
15.15% | 4.17% | 5.06% | 11.68% | 9.24% | (7.02%) | 13.27% | 7.77% | (7.22%) | 9.82% |
Accounts Receivable Turnover |
5.48 | 5.31 | 5.32 | 5.38 | 5.44 | 6.74 | 7.00 | 6.56 | 7.40 | 8.40 |
Accounts Payable Turnover |
1.83 | 2.03 | 1.32 | 0.92 | 1.11 | 1.44 | 1.22 | 1.10 | 1.11 | 1.10 |
Inventory Turnover |
4.65 | 5.12 | 4.86 | 5.92 | 6.81 | 9.44 | 12.44 | 14.00 | 15.01 | 19.76 |
Average Days of Payables |
205.92 | 230.96 | 156.89 | 489.40 | 416.05 | 274.50 | 267.23 | 402.63 | 310.77 | 474.22 |
Days of Inventory on Hand |
99.12 | 68.86 | 90.14 | 74.05 | 67.45 | 45.65 | 36.42 | 27.02 | 29.77 | 25.76 |
Average Receivables |
938.78 | 798.36 | 694.22 | 630.59 | 549.15 | 395.40 | 308.20 | 286.95 | 207.53 | 131.60 |
Average Payables |
203.70 | 153.53 | 193.57 | 224.83 | 135.44 | 91.21 | 93.74 | 85.75 | 71.64 | 52.84 |
Average Inventory |
79.97 | 60.92 | 52.48 | 34.95 | 22.16 | 13.91 | 9.18 | 6.72 | 5.29 | 2.94 |
Average Assets |
6,201.15 | 6,113.21 | 6,311.55 | 5,387.17 | 4,247.14 | 3,493.83 | 3,036.26 | 2,474.17 | 1,970.59 | 1,323.02 |
Average Common Equity |
4,307.55 | 4,318.73 | 4,779.98 | 4,070.06 | 3,190.64 | 2,604.84 | 2,262.19 | 1,778.30 | 1,025.05 | 295.31 |
Columns are period end dates